Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor

American Journal of Dermatopathology

Volumn 37, Issue 2, 2015, Pages 138-144

  Kampilafkos, Panagiotis ^a   Melachrinou, Maria ^a   Kefalopoulou, Zinovia ^a,b   Lakoumentas, John ^c   Sotiropoulou Bonikou, Georgia ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

epigenetics; EZH2; H3K27me3; H3K4me2; invasion front; malignant melanoma

Indexed keywords

H3K4ME2 PROTEIN; H3K4ME3 PROTEIN; PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; HISTONE; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASION FRONT; KERATINOCYTE; MALE; MELANOMA CELL; NEVUS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENTINEL LYMPH NODE; TUMOR INVASION; AGED; CANCER STEM CELL; CHEMISTRY; COMPARATIVE STUDY; GENETIC EPIGENESIS; GENETICS; MELANOMA; METHYLATION; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SKIN TUMOR;

ADULT; AGED; EPIGENESIS, GENETIC; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METHYLATION; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 2; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84923865385     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31828a2d54     Document Type: Article

References (32)

1. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82:364-380
2. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345-349
3. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 2011;21:502-517
4. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy?. J Pathol. 2011;223:147-161
5. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10:457-469
6. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148-1159
7. Schwabe M, Lubbert M. Epigenetic lesions in malignant melanoma. Curr Pharm Biotechnol. 2007;8:382-387
8. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125: 315-326
9. Chang CJ, Hung MC. The role of EZH2 in tumuor progression. Br J Cancer. 2012;106:243-247
10. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24:268
11. McHugh JB, Fullen DR, Ma L, et al. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol. 2007;34:597-600
12. Fan T, Jiang S, Chung N, et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res. 2011;9:418-429
13. Iliou MS, Lujambio A, Portela A, et al. Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Epigenetics. 2011;6:1344-1353
14. Mills AA. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer. 2010;10:669-682
15. Anelli V, Santoriello C, Distel M, et al. Global repression of cancer gene expression in a zebrafish model of melanoma is linked to epigenetic regulation. Zebrafish. 2009;6:417-424
16. Brabletz S, Schmalhofer O, Brabletz T. Gastrointestinal stem cells in development and cancer. J Pathol. 2009;217:307-317
17. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-323
18. Zlobec I, Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol. 2009;15:5898-5906
19. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715
20. Battula VL, Evans KW, Hollier BG, et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells. 2010;28:1435-1445
21. Brabletz T, Jung A, Spaderna S, et al. Opinion: migrating cancer stem cells-An integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5:744-749
22. Sigalotti L, Covre A, Fratta E, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med. 2010;8:56
23. Hostettler L, Zlobec I, Terracciano L, et al. ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J Gastroenterol. 2010;16:732-739
24. Atsumi N, Ishii G, Kojima M, et al. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun. 2008;373:36-41
25. He X, Marchionni L, Hansel DE, et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells. 2009; 27:1487-1495
26. Wu M-Z, Tsai Y-P, Yang M-H, et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell. 2011;43:811-822
27. Lin T, Ponn A, Hu X, et al. Requirement of the histone demethylase LDS1 in Snai1-mediated transcriptional repression during epithelial- mesenchymal transition. Oncogene. 2010;29:4896-4904
28. Balasubramanian S, Adhikary G, Eckert RL. The Bmi-1 polycomb protein antagonizes the (2)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis. 2010;31:496-503
29. Blair LP, Cao J, Zou MR, et al. Epigenetic regulation by lysine demethylase 5 (KDM5) enzymes in cancer. Cancers (Basel). 2011; 1:1383-1404
30. Wang J, Lu F, Ren Q, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011;71:7238-7249
31. Xiao Y. Enhancer of zeste homolog 2: a potential target for tumor therapy. Int J Biochem Cell Biol. 2011;43:474-477
32. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of polycombrepressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050-1063